Skip to Content
Merck
CN

Key Documents

View All Documentation

SML3829

CADD522

≥98% (HPLC)

Synonym(s):

2-[(3,4-Dichlorophenyl)carbamoyl]bicyclo[2.2.1]hept-5-ene-3-carboxylic acid, 3-[(3,4-Dichlorophenyl)carbamoyl]bicyclo[2.2.1]hept-5-ene-2-carboxylic acid, 3-[[(3,4-Dichlorophenyl)amino]carbonyl]bicyclo[2.2.1]hept-5-ene-2-carboxylic acid

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C15H13Cl2NO3
CAS Number:
199735-88-1
Molecular Weight:
326.17
UNSPSC Code:
12352200
NACRES:
NA.21
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
100
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

-10 to -25°C

SMILES string

O=C(C1C2C=CC(C1C(NC3=CC=C(C(Cl)=C3)Cl)=O)C2)O

InChI

1S/C15H13Cl2NO3/c16-10-4-3-9(6-11(10)17)18-14(19)12-7-1-2-8(5-7)13(12)15(20)21/h1-4,6-8,12-13H,5H2,(H,18,19)(H,20,21)

InChI key

YSDNWNOGHQYWPK-UHFFFAOYSA-N

Related Categories

Biochem/physiol Actions

CADD522 is a cell-permeable, bioavailable, non-toxic carbamoyl-bicycloheptene-carboxylate that inhibits RUNX2-DNA binding, thereby increases RUNX2 stability, upregulates RUNX2 expression levels and downregulates RUNX2 responsive genes transcription. CADD522 inhibits mitochondrial oxidative phosphorylation by decreasing the mitochondrial oxygen consumption rate and ATP production in human breast cancer cells in a RUNX2-independent manner. CADD-522 suppresses in vivo tumor growth and metastasis, and appreciably prolongs the survival rates without the need for surgery or chemotherapy.
Cell-permeable, bioavailable, non-toxic carbamoyl-bicycloheptene-carboxylate that inhibits RUNX2-DNA binding, thereby increases RUNX2 stability

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000263853
0000263854
0000257132
0000257132
0000263854

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Targeting breast cancer metabolism with a novel inhibitor of mitochondrial ATP synthesis
Oncotarget, 11(43), 3863-3885 (2020)
YBX1-interacting small RNAs and RUNX2 can be blocked in primary bone cancer using CADD522
Journal of bone oncology, 39, 100474-100474 (2023)
Myoung Sook Kim et al.
Oncotarget, 8(41), 70916-70940 (2017-10-21)
The RUNX2 transcription factor promotes breast cancer growth and metastasis through interactions with a variety of cofactors that activate or repress target genes. Using a direct drug discovery approach we identified CADD522 as a small molecule that inhibits the DNA

Global Trade Item Number

SKUGTIN
SML3829-50MG04065270323897
SML3829-10MG04065270323880

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service